Cetirizine: what an H1 antihistamine changes

01 / A specific target

Cetirizine changes the response to histamine.

Cetirizine targets H1 receptors and can relieve allergic sneezing, itching and runny nose. It also treats hives when indicated. It does not remove allergens, eradicate infection or suppress the entire immune system.^[1]

Histamine acts through several receptor types. Favoring an inactive H1 state does not abolish histamine synthesis, block every histamine receptor or prevent release of all allergic mediators.

02 / From allergen to symptoms

An inverse agonist favors an inactive state.

In an immediate allergic response, an allergen can cross-link IgE bound to mast cells, helping trigger release of histamine and other mediators. Histamine acting at H1 receptors contributes to effects including itch, vascular permeability and sensory-nerve activation. Those processes help explain the watery, itchy symptoms an H1 medicine can relieve.

Receptors are dynamic proteins that can occupy different conformations. A neutral antagonist blocks an agonist’s action without changing basal receptor activity in the simple model. An inverse agonist also reduces constitutive activity by favoring an inactive conformation. Experiments with human H1 receptors demonstrated inverse agonism by cetirizine and several other clinically used antihistamines.^[2]

Receptor pharmacology does not determine a personal dose. Binding affinity, tissue exposure and clinical outcomes require separate evidence; expression-system findings establish a mechanism, while trials and labeling address use and safety.

03 / Peripheral does not mean impossible in the brain

Drowsiness remains possible.

Cetirizine is often described as a second-generation or less-sedating antihistamine. Compared with many older H1 drugs, it has more limited brain penetration. Nonetheless, drowsiness can occur. The official product labeling warns about driving or operating machinery and notes that alcohol, sedatives and tranquilizers can increase drowsiness.^[3]

Brain histamine signaling contributes to wakefulness, so central H1 blockade can cause sedation. Response varies with factors including kidney function, age, other medicines and formulation. Safe use depends on product-specific directions and clinical context.

04 / Current safety context

Post-discontinuation itching after long-term use

In 2025 the FDA required a warning about rare but severe itching after stopping long-term oral cetirizine or levocetirizine. Reports typically followed daily use for months or years and began within days of stopping. Spontaneous reports identify a safety concern but do not provide a reliable incidence rate for everyone using the medicine.^[4]

Symptoms after stopping require assessment of treatment history, the original condition and other causes. FDA advises discussing planned long-term use and seeking professional advice for severe post-discontinuation itching. The warning does not establish a universal tapering regimen or justify automatic abrupt discontinuation.